Johnson & Johnson Stelara — Percent Change (as a percent) increased by 4.5% to -123.0% in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 550.8%, from -18.9% to -123.0%. This is a positive signal — higher values indicate stronger performance for this metric.
Positive growth indicates expanding market share or increased utilization, whereas negative growth suggests potential market saturation, loss of exclusivity, or competitive displacement.
This metric measures the period-over-period growth rate of net sales for a specific pharmaceutical product. It provides...
Comparable to year-over-year or quarter-over-quarter revenue growth rates for specific product lines or therapeutic areas reported by peer pharmaceutical firms.
jnj_segment_stelara_percent_change_as_a_percent| Q2 '21 | Q3 '21 | Q4 '21 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | 63.1% | 104.6% | 69.4% | 21.3% | 41.6% | 6.6% | 21.3% | 52.3% | 2.7% | 10.2% | -18.9% | -8.5% | -102.4% | -128.8% | -123% |
| QoQ Change | — | +65.8% | -33.7% | -69.3% | +95.3% | -84.1% | +222.7% | +145.5% | -94.8% | +277.8% | -285.3% | +55.0% | <-999% | -25.8% | +4.5% |
| YoY Change | — | — | — | -66.2% | -60.2% | -90.5% | +0.0% | +25.7% | — | -52.1% | -136.1% | — | <-999% | <-999% | -550.8% |
We use cookies for analytics. See our Privacy and Cookie Policy.